EU pharma R&D squeezed by funding gaps, slow approvals, US MFN rules

European pharmaceutical research faces mounting pressure from reduced financing, sluggish regulatory approvals, and a fragmented EU market, compounded by Trump administration most-favored-nation pricing regulations. The combination threatens the region's competitiveness in drug innovation, though the exact near-term impact on R&D pipelines remains uncertain.